APA

Mendiola M., Martínez-Marin V., Herranz J., Heredia V., Yébenes L., Zamora P., Castelo B., Pinto Á., Miguel M., Díaz E., Gámez A., Fresno J. Á., Ramírez de Molina A., Hardisson D., Espinosa E. & Redondo A. (20180117). Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. : Oncotarget.

Chicago

Mendiola Marta, Martínez-Marin Virginia, Herranz Jesús, Heredia Victoria, Yébenes Laura, Zamora Pilar, Castelo Beatriz, Pinto Álvaro, Miguel María, Díaz Esther, Gámez Angelo, Fresno Juan Ángel, Ramírez de Molina Ana, Hardisson David, Espinosa Enrique and Redondo Andrés. 20180117. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. : Oncotarget.

Harvard

Mendiola M., Martínez-Marin V., Herranz J., Heredia V., Yébenes L., Zamora P., Castelo B., Pinto Á., Miguel M., Díaz E., Gámez A., Fresno J. Á., Ramírez de Molina A., Hardisson D., Espinosa E. and Redondo A. (20180117). Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. : Oncotarget.

MLA

Mendiola Marta, Martínez-Marin Virginia, Herranz Jesús, Heredia Victoria, Yébenes Laura, Zamora Pilar, Castelo Beatriz, Pinto Álvaro, Miguel María, Díaz Esther, Gámez Angelo, Fresno Juan Ángel, Ramírez de Molina Ana, Hardisson David, Espinosa Enrique and Redondo Andrés. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. : Oncotarget. 20180117.